The firm has billed commercial insurers for more than 17,000 tests and reported test results for more than 15,000 Medicare patients without receiving payment.
While the overall number of oncologists who ordered the company's tests in the third quarter did not change, the frequency with which they reordered fell by about 7 percent.
The GeneReader NGS system, which is geared toward clinical laboratories, is an integrated package with multiple components that cover all steps to analyze a tissue sample.
AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
The firm is conducting a multi-center prospective clinical study to validate its liquid biopsy ctDNA test, which it plans to launch for pharma customers this year and commercially in 2016.
Gene panel testing of cancer patients helps clinicians identify actionable mutations, according to presenters at this year's AACC meeting.
EDGC will have exclusive distribution rights in South Korea for the OncoDEEP Dx panel and other technologies, while physicians there will be able to access the OncoShare web platform.
Last month, the company presented results from a pilot study at the Worldwide Innovative Networking (WIN) Symposium in Paris.
Deck: The panels, which cover lung, colon, brain, and thyroid cancer as well as melanoma and gastrointestinal stromal tumors, target newly diagnosed patients.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.